Skip to main content
Log in

Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

In order to study the role of the p16INK4A(MTS1/CDKN2a) tumor suppressor in breast cancer, we analyzed p16 protein expression in 60 breast cancer samples which were also analyzed for expression of Rb, Ki67, HER2/neu, and estrogen and progesterone receptors (ER, PR). P16 expression was investigated by two methods: western blotting (WB) followed by densitometry, and immunohistochemistry (IHC). The Rb status was studied by western blotting, and expression of Ki67, HER2/neu, ER, and PR was analyzed immunohistochemically. P16-negative results were found in 18% of the carcinomas by WB, but in only one case by IHC and were not associated with established prognostic parameters. In contrast, p16 overexpression which was detected by WB and IHC in 15% and 25% of the tumors, respectively, was significantly associated with unfavorable prognostic indicators. High p16 expression as detected by both methods correlated significantly with high grading and a negative estrogen receptor status. In addition, a significant association of p16 staining with inverse progesterone receptor status and high Ki67 expression was found with IHC. No correlation of p16 expression with clinical stage, HER2/neu immunostaining, Rb expression or Rb phosphorylation was found. Comparison of western blot results and immunohistochemistry suggests that both nuclear and cytoplasmic immunoreactivity in tumor cells is specific and due to p16 expression. We conclude that high p16 reactivity (both nuclear and cytoplasmic) is indicative of a more undifferentiated, malignant phenotype in mammary carcinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ruas M, Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-F177, 1998

    Google Scholar 

  2. Quesnel B, Fenaux P, Philippe N, Fournier J, Bonneterre J, Preudhomme C, Peyrat JP: Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer 72: 351-353, 1995

    Google Scholar 

  3. Berns EM, Klijn JG, Smid M, van Staveren IL, Gruis NA, Foekens JA: Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer 72: 964-967, 1995

    Google Scholar 

  4. Musgrove EA, Lee CSL, Cornish AL, Swarbrick A, Sutherland RL: Antiprogest in inhibition of cell cycle progression in T47-D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11: 54-66, 1997

    Google Scholar 

  5. Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM: Preferential loss of expression of p16 (INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res 2: 1993-1998, 1996

    Google Scholar 

  6. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995

    Google Scholar 

  7. Van Zee KJ, Calvano JE, Bisogna M: Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 16: 2723-2727, 1998

    Google Scholar 

  8. Kelley MJ, Otterson GA, Kaye FJ, Popescu NC, Johnson BE, Dipaolo JA: CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 63: 226-230, 1995

    Google Scholar 

  9. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histological parameters. Int J Cancer 79: 71-75, 1998

    Google Scholar 

  10. Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84: 553-558, 1999

    Google Scholar 

  11. Milde-Langosch K, Ocon E, Becker G, Löning T: p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int J Cancer 79: 61-65, 1998

    Google Scholar 

  12. Milde-Langosch K, Riethdorf L, Bamberger A-M, Löning T: P16/MTS1 and pRb expression in endometrial carcinomas. Virchows Arch 434: 23-28, 1999

    Google Scholar 

  13. Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M, Wallwiener D, Sinn H-P: Aberrant cytoplasmic expression of the p16 prote in in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 78: 1661-1668, 1998

    Google Scholar 

  14. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262-7266, 1992

    Google Scholar 

  15. Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, Nicholson RI, Robertson JFR, Sutherland RL: INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 6: 2777-2787, 2000

    Google Scholar 

  16. Geradts J, Wilson PA: High frequency of aberrant p16 INK4A expression in human breast cancer. Am J Pathol 149: 15-20, 1996

    Google Scholar 

  17. Kaneko S, Nishioka J, Tanaka M, Nakashima K, Nobori T: Transcriptional regulation of the CDK inhibitor p16INK4a gene by a novel pRb-associated repressor, RBAR1. Biochem Mol Biol Int 47: 205-215, 1999

    Google Scholar 

  18. Huschtscha LI, Noble JR, Neumann AA, Moy EL, Barry P, Melki JR, Clark SJ, Redell RR: Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 58: 3508-3512, 1998

    Google Scholar 

  19. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K: Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 93: 15215-15220, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milde-Langosch, K., Bamberger, AM., Rieck, G. et al. Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype. Breast Cancer Res Treat 67, 61–70 (2001). https://doi.org/10.1023/A:1010623308275

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010623308275

Navigation